NDAORALTABLETPriority Review
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Priority Review
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing three nucleoside/non-nucleoside reverse transcriptase inhibitors (lamivudine, zidovudine, and efavirenz) used to treat HIV-1 infection. The combination works by inhibiting viral reverse transcriptase, preventing HIV replication and reducing viral load. This oral tablet formulation simplifies the regimen for patients requiring antiretroviral therapy.
Pre-Launch
Pre-launch stage indicates early-phase commercial infrastructure building; limited team size expected until regulatory approval and market entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Careers on this pre-launch asset will focus on navigating regulatory approval, establishing market access in HIV treatment settings, and competing in a mature therapeutic category. This role offers exposure to infectious disease marketing and global health considerations but limited opportunity for scientific innovation or long-term brand stewardship due to generic exposure.
Brand Manager
Worked on LAMIVUDINE; ZIDOVUDINE; EFAVIRENZ at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.